JP2021534114A5 - - Google Patents
Info
- Publication number
- JP2021534114A5 JP2021534114A5 JP2021506715A JP2021506715A JP2021534114A5 JP 2021534114 A5 JP2021534114 A5 JP 2021534114A5 JP 2021506715 A JP2021506715 A JP 2021506715A JP 2021506715 A JP2021506715 A JP 2021506715A JP 2021534114 A5 JP2021534114 A5 JP 2021534114A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- alkyl
- aryl
- heteroaryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718925P | 2018-08-14 | 2018-08-14 | |
| US62/718,925 | 2018-08-14 | ||
| PCT/US2019/046405 WO2020036995A1 (en) | 2018-08-14 | 2019-08-13 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534114A JP2021534114A (ja) | 2021-12-09 |
| JP2021534114A5 true JP2021534114A5 (enExample) | 2022-08-19 |
Family
ID=69525833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506715A Pending JP2021534114A (ja) | 2018-08-14 | 2019-08-13 | 併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210161909A1 (enExample) |
| JP (1) | JP2021534114A (enExample) |
| CN (1) | CN112839651A (enExample) |
| AU (1) | AU2019322858A1 (enExample) |
| EA (1) | EA202190360A1 (enExample) |
| IL (1) | IL280729A (enExample) |
| MX (1) | MX2021001764A (enExample) |
| TW (1) | TW202021592A (enExample) |
| WO (1) | WO2020036995A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630118A4 (en) | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | COMBINATION THERAPY |
| IL315315A (en) * | 2022-03-01 | 2024-10-01 | Mei Pharma Inc | Combined treatment with PI3K inhibitor and PD1 inhibitor |
| CN118949002A (zh) * | 2024-10-15 | 2024-11-15 | 杭州阿克索生物科技有限责任公司 | 一种宫颈癌细胞抑制组合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101209397B1 (ko) * | 2006-06-21 | 2012-12-06 | 피라말 라이프 사이언시스 리미티드 | 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법 |
| CN107501241B (zh) * | 2011-03-28 | 2020-10-13 | 梅制药公司 | 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途 |
| WO2014055647A1 (en) * | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| WO2016024232A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| IL295472B2 (en) * | 2016-03-28 | 2024-10-01 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| CN109982687A (zh) * | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| EP3630118A4 (en) * | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | COMBINATION THERAPY |
| MX2020001727A (es) * | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
-
2019
- 2019-08-13 WO PCT/US2019/046405 patent/WO2020036995A1/en not_active Ceased
- 2019-08-13 MX MX2021001764A patent/MX2021001764A/es unknown
- 2019-08-13 AU AU2019322858A patent/AU2019322858A1/en not_active Abandoned
- 2019-08-13 US US17/268,049 patent/US20210161909A1/en not_active Abandoned
- 2019-08-13 EA EA202190360A patent/EA202190360A1/ru unknown
- 2019-08-13 CN CN201980067618.0A patent/CN112839651A/zh active Pending
- 2019-08-13 JP JP2021506715A patent/JP2021534114A/ja active Pending
- 2019-08-14 TW TW108128842A patent/TW202021592A/zh unknown
-
2021
- 2021-02-08 IL IL280729A patent/IL280729A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517116A5 (enExample) | ||
| JP2021523159A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2024516997A5 (enExample) | ||
| JP2021512059A5 (enExample) | ||
| JP2022071077A5 (enExample) | ||
| JP2022536540A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| JP2023531709A5 (enExample) | ||
| RU2018137687A (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
| JP2015518894A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| JP2020532556A (ja) | 癌を処置するための併用療法 | |
| JP2014513731A5 (enExample) | ||
| JP2014509647A5 (enExample) | ||
| US20200405697A1 (en) | Antitumor Agent | |
| JP2021529174A5 (enExample) | ||
| JP2013527847A5 (enExample) | ||
| JP2021523169A5 (enExample) | ||
| JP2023531495A5 (enExample) | ||
| JP2024516353A5 (enExample) | ||
| JP2016513128A5 (enExample) | ||
| KR102904026B1 (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| CN116323590A (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |